XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:        
Total revenue $ 75,592 $ 60,370 $ 216,239 $ 152,178
Operating expenses:        
Research and development 10,773 8,006 29,316 19,591
Selling and marketing 25,678 21,670 73,433 57,628
General and administrative 17,600 20,749 58,310 82,504
Intangible asset amortization 5,213 4,983 16,090 10,507
Total operating expenses 85,272 77,051 251,900 221,748
Loss from operations (9,680) (16,681) (35,661) (69,570)
Other income (loss), net 805 1,202 2,675 (762)
Loss before income taxes (8,875) (15,479) (32,986) (70,332)
Income tax benefit (152) (1,350) (270) (5,297)
Net loss $ (8,723) $ (14,129) $ (32,716) $ (65,035)
Net loss per common share, basic (in USD per share) $ (0.12) $ (0.20) $ (0.46) $ (0.97)
Net loss per common share, diluted (in USD per share) $ (0.12) $ (0.20) $ (0.46) $ (0.97)
Shares used to compute net loss per common share, basic (in shares) 71,656,694 69,743,733 71,456,008 66,820,654
Shares used to compute net loss per common share, diluted (in shares) 71,656,694 69,743,733 71,456,008 66,820,654
Testing revenue        
Revenue:        
Total revenue $ 64,577 $ 50,897 $ 180,275 $ 134,768
Operating expenses:        
Cost of revenue 19,816 16,073 55,923 42,494
Product revenue        
Revenue:        
Total revenue 3,314 2,959 9,401 8,706
Operating expenses:        
Cost of revenue 1,981 1,491 5,202 4,304
Biopharmaceutical and other revenue        
Revenue:        
Total revenue 7,701 6,514 26,563 8,704
Operating expenses:        
Cost of revenue $ 4,211 $ 4,079 $ 13,626 $ 4,720